Nuclear Retirement Anxiety
As nuclear power plants age, concerns grow over financing, complexity, and safety of decommissioning
Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
April 1, 2013 Cover
Volume 91, Issue 13
As nuclear power plants age, concerns grow over financing, complexity, and safety of decommissioning
Cover image:
Credit:
Nuclear Power
Specialties Are In The Crosshairs As Chemical Firms Turn To Acquisitions To Piece Together New Businesses
Major chemical firms are on the prowl for companies that will jump-start their transformation strategies
Toward Sustainable Electronics
To reduce electronic waste, a diverse team of engineers searches for new materials, training a savvy workforce along the way
-
The Mystery Of Hot Gold Nanoparticles
An unintended route to magnetism may lead to thermal cancer treatment
-
Transition: BioReliance Settles In With Sigma-Aldrich’s SAFC Division
-
Streamlining Chemical Security
New regulatory tools may accelerate the approval process for facility antiterrorism plans
ADVERTISEMENT
Science Concentrates
DNA Damage Linked To Alzheimer’s
Mice engineered to produce the disease-related peptide amyloid-beta have more breakage in their nerve cell DNA than do nonengineered mice